All mothers (n=18)* | |
Mean (SD), unless otherwise stated | |
Age, years | 33.7 (4.2) |
Weight, kg | 68.9 (9.6)† |
BMI, kg/m² | 23.6 (3.0)† |
Location, n | |
USA/Canada‡ | 10 |
Switzerland | 5 |
The Netherlands | 3 |
Mother’s indication for CZP treatment, n† | |
Rheumatoid arthritis | 7 |
Crohn’s disease | 5 |
Psoriatic arthritis | 3 |
Axial spondyloarthritis/ankylosing spondylitis | 2 |
All infants (n=17) | |
Median (min–max), unless otherwise stated | |
Female, n (%) | 11 (64.7) |
Gestational age at birth, weeks | 40.0 (39.0–41.7) |
Weight at birth, kg | 3.5 (2.6–4.1) |
Length at birth, cm | 50.7 (48.0–57.0) |
Age at time of mother’s first sample, months | 2.8 (1.6–16.8) |
Age at time of mother’s first sample, n (%) | |
≤6 months | 13 (76.5) |
>6 months–≤12 months | 2 (11.8) |
≥12 months–≤18 months | 2 (11.8) |
*Includes one screen failure.
†n=17.
‡One Canadian patient enrolled under the central USA site, which was approved by the Canadian central IRB.
BMI, body mass index; IRB, institutional review board.